FDA Expands argenx's VYVGART to All Adult Myasthenia Gravis Serotypes, Reaching Seronegative Patients for the First Time
The May 8 sBLA approval extends efgartigimod's label to MuSK, LRP4 and triple-seronegative gMG patients after the 119-patient ADAPT SERON trial hit its MG-ADL endpoint with a 3.35-point improvement at week 4 (p=0.0068).
3 min read4 sources